A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

Seasonal strength is from May until the end of September.  It is an opportunity to take some money off the table.

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

(A Top Pick March 10/15. Down 39.56%.) For about 3 years Biotech was one of the leading groups in the market. He stays in positions as long as they work, and runs Stop Losses. In July, biotech as a group rolled over and he got stopped out at about $308-$310.

Has been watching this for a little while. It doesn’t trade at an extreme valuation and they have a nice pipeline. A drug that propelled them recently was their new Alzheimer’s one that is still in testing. A very promising drug. In a short time they are going to come out with the results of a new test on it. He thinks the market will react on this, so he would be hesitant to buy in front of that. If you can buy this in the $350-$375 area, it has a lot of promise.